Background: This study aimed to evaluate the bioequivalence (BE) of two oral formulations of ursodeoxycholic acid (UDCA), administered as 300 mg tablets (two tablets; 600 mg total dose), and to assess the pharmacokinetics (PK) and bioequivalence (BE) of UDCA in 24 healthy male subjects. Methods: A Phase I, randomized, open-label, two-period, two-sequence, two-treatment, single-dose crossover study was conducted under fed conditions. Subjects received a 600-mg oral dose of either the test or reference formulation in each period. Plasma PK parameters (Cmax and AUC0-72) for unconjugated and total UDCA were quantified using a validated LC-MS/MS method. Results: The geometric mean ratios (test/reference) and corresponding 90% confidence intervals (CIs) for unconjugated UDCA were: Cmax: 103.42% (90.34% - 118.40%), AUC0-t: 105.09% (94.95% - 116.30%). For total UDCA (conjugated + unconjugated), the results were: Cmax: 100.27% (89.50% - 112.33%), AUC0-72: 96.96% (80.49% - 116.80%). The PK profiles of the test and reference formulations were similar, as demonstrated by the 90% CIs of Cmax and AUC0-72 parameters falling within the accepted BE range of 80% - 125%. Conclusions: Baseline-corrected Cmax and AUC0-72 for unconjugated and total UDCA met the regulatory criteria for bioequivalence. The test formulation is therefore bioequivalent to the reference formulation. No adverse events were reported.
References
[1]
Huang, L., Wei, W., Huang, X., Li, X., Liu, H., Gui, L., et al. (2023) High-Fat Diets Enhance and Delay Ursodeoxycholic Acid Absorption but Elevate Circulating Hydrophobic Bile Salts. FrontiersinPharmacology, 14, Article ID: 1168144. https://doi.org/10.3389/fphar.2023.1168144
[2]
Bessone, F., Hillotte, G.L., Ahumada, N., Jaureguizahar, F., Medeot, A.C. and Roma, M.G. (2024) UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis. SeminarsinLiverDisease, 44, 1-22. https://doi.org/10.1055/s-0044-1779520
Hall, L., Halle-Smith, J., Evans, R., Toogood, G., Wiggins, T., Markar, S.R., et al. (2023) Ursodeoxycholic Acid in the Management of Symptomatic Gallstone Disease: Systematic Review and Clinician Survey. BJSOpen, 7, zrac152. https://doi.org/10.1093/bjsopen/zrac152
[6]
Hountondji, L., Faure, S., Palassin, P., Pageaux, G., Maria, A.T.J. and Meunier, L. (2025) Ursodeoxycholic Acid Alone Is Effective and Safe to Treat Cholestatic Checkpoint Inhibitor‐Induced Liver Injury. LiverInternational, 45, e70073. https://doi.org/10.1111/liv.70073
[7]
Yan, Y., Wang, W., Yan, A., Zhu, H. and Meng, Q. (2025) β-Sitosterol Protects against Anit-Induced Hepatotoxicity and Cholestasis via FXR Activation. ToxicologyinVitro, 104, Article 106020. https://doi.org/10.1016/j.tiv.2025.106020
[8]
Cortez‐Pinto, H., Liberal, R., Lopes, S., Machado, M.V., Carvalho, J., Dias, T., et al. (2021) Predictors for Incomplete Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis. Data from a National Registry of Liver Disease. UnitedEuropeanGastroenterologyJournal, 9, 699-706. https://doi.org/10.1002/ueg2.12095
[9]
Saffioti, F., Gurusamy, K.S., Eusebi, L.H., Tsochatzis, E., Davidson, B.R. and Thorburn, D. (2017) Pharmacological Interventions for Primary Biliary Cholangitis: An Attempted Network Meta-Analysis. CochraneDatabaseofSystematicReviews, No. 3, CD011648. https://doi.org/10.1002/14651858.cd011648.pub2
[10]
Sathe, A.G., Tuite, P., Chen, C., Ma, Y., Chen, W., Cloyd, J., et al. (2020) Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients with Parkinson’s Disease—A Pilot Study. TheJournalofClinicalPharmacology, 60, 744-750. https://doi.org/10.1002/jcph.1575
[11]
Combes, B., Luketic, V.A., Peters, M.G., Zetterman, R.K., Garcia-Tsao, G., Munoz, S.J., et al. (2004) Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis. American Journal of Gastroenterology, 99, 264-268. https://doi.org/10.1111/j.1572-0241.2004.04047.x
[12]
Pinto, C., Ninfole, E., Benedetti, A., Marzioni, M. and Maroni, L. (2021) Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases. Cells, 10, Article 2772. https://doi.org/10.3390/cells10102772
[13]
Simental‐Mendía, M., Sánchez‐García, A. and Simental‐Mendía, L.E. (2020) Effect of Ursodeoxycholic Acid on Liver Markers: A Systematic Review and Meta‐Analysis of Randomized Placebo-Controlled Clinical Trials. British Journal of Clinical Pharmacology, 86, 1476-1488. https://doi.org/10.1111/bcp.14311
[14]
Ni, Y., Guan, X., Gao, X., Wang, Y., Qin, D., Shan, Z., et al. (2025) Adverse Events of Ursodeoxycholic Acid: A Real-World Pharmacovigilance Study Using FAERS (2004-2023). FrontiersinMedicine, 12, Article ID: 1574308. https://doi.org/10.3389/fmed.2025.1574308
[15]
ICMR (2025) Indian Council Medical Research. http://www.icmr.gov.in
[16]
Singh, N., Madkaikar, N., Gokhale, P. and Parmar, D. (2020) New Drugs and Clinical Trials Rules 2019: Changes in Responsibilities of the Ethics Committee. PerspectivesinClinicalResearch, 11, 37-43. https://doi.org/10.4103/picr.picr_208_19
[17]
World Medical Association (2013) World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA, 310, 2191-2194.
[18]
ICH (2025) International Council for Harmonization of Technical Requirements for Pharmaceutical for Human Use. Guidelines for Good Clinical Practice (E6)-International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://ichgcp.net
[19]
FDA (2025) Product-Specific Guidance for Generic Development. Ursodeoxycholic Acid Oral Tablets. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019594.pdf
[20]
Sundd Singh, S., Shah, H., Gupta, S., Jain, M., Sharma, K., Patel, H., et al. (2004) Validation of LC/MS Electrospray Ionisation Method for the Estimation of Ursodiol in Human Plasma and ITS Application in Bioequivalence Study. AnnalidiChimica, 94, 951-959. https://doi.org/10.1002/adic.200490117
[21]
Pinto, M.C., Chorfi Berton, D., Cavenatti de Oliveira, A., Lázaro, C.M. and Aparecida Calafatti Carandina, S. (2019) Method Development and Validation of Ursodiol and Its Major Metabolites in Human Plasma by HPLC-Tandem Mass Spectrometry. ClinicalPharmacology: AdvancesandApplications, 11, 1-13. https://doi.org/10.2147/cpaa.s187519
[22]
Williams, C.N., Al‐Knawy, B. and Blanchard, (2000) Bioavailability of Four Ursodeoxycholic Acid Preparations. Alimentary Pharmacology & Therapeutics, 14, 1133-1139. https://doi.org/10.1046/j.1365-2036.2000.00817.x
[23]
Setchell, K.D.R., Galzigna, L., O’Connell, N., Brunetti, G. and Tauschel, H. (2005) Bioequivalence of a New Liquid Formulation of Ursodeoxycholic Acid (Ursofalk Suspension) and Ursofalk Capsules Measured by Plasma Pharmacokinetics and Biliary Enrichment. AlimentaryPharmacology&Therapeutics, 21, 709-721. https://doi.org/10.1111/j.1365-2036.2005.02385.x
[24]
ICH (2024) Harmonised Guideline. Bioequivalence for Immediate-Release Solid Oral Dosage Form M13A. https://database.ich.org/sites/default/files/ICH_M13A_Step4_Final_Guideline_2024_0723.pdf
[25]
Lluís, N., Asbun, H., Basso, S., Corzo-Zamora, N., Gelrud, A., Guzmán-Calderón, E., et al. (2023) Survey on Initial Management of Acute Pancreatitis in Latin America. GastroenterologíayHepatología (EnglishEdition), 46, 603-611. https://doi.org/10.1016/j.gastre.2023.01.002
[26]
Latorre S, G., Ivanovic-Zuvic s, D., Corsi S, Ó., Valdivia C, G., Margozzini M, P., Olea O, R., et al. (2015) Cobertura de la estrategia preventiva de cáncer de vesícula biliar en Chile: Resultados de la Encuesta Nacional de Salud 2009-2010. Revista Médica de Chile, 143, 158-167. https://doi.org/10.4067/s0034-98872015000200002
[27]
Nakano, L.A., Cançado, E.L.R., Chaves, C.E., Madeira, M.C.V., Katayose, J.T., Nabeshima, M.A., et al. (2020) A Randomized Crossover Trial to Assess Therapeutic Efficacy and Cost Reduction of Acid Ursodeoxycholic Manufactured by the University Hospital for the Treatment of Primary Biliary Cholangitis. BMCGastroenterology, 20, Article No. 253. https://doi.org/10.1186/s12876-020-01399-5
[28]
Lee, S.H., Jang, D.K., Yoo, M., Hwang, S., Ryu, S., Kwon, O.K., et al. (2020) Efficacy and Safety of Ursodeoxycholic Acid for the Prevention of Gallstone Formation after Gastrectomy in Patients with Gastric Cancer: The PEGASUS-D Randomized Clinical Trial. JAMA Surgery, 155, 703-711. https://doi.org/10.1001/jamasurg.2020.1501
[29]
van de Meeberg, P.C., Wolfhagen, F.H.J., Van Berge-Henegouwen, G.P., Salemans, J.M.J.I., Tangerman, A., van Buuren, H.R., et al. (1996) Single or Multiple Dose Ursodeoxycholic Acid for Cholestatic Liver Disease: Biliary Enrichment and Biochemical Response. JournalofHepatology, 25, 887-894. https://doi.org/10.1016/s0168-8278(96)80293-5
[30]
Pena, E., Inatti, A., Taly, A., Chacón, J.G. and Serrano-Martin, X. (2023) Bioequivalence Assessment of Two Formulations of Empagliflozin in Healthy Adult Subjects. AmericanJournalofPharmacotherapyandPharmaceuticalSciences, 2, Article 19. https://doi.org/10.25259/ajpps_2023_019
[31]
Pena, E., Inatti, A., Taly, A., Chacón, J. and Serrano-Martin, X. (2024) A Bioequivalence Study of Empagliflozin/Metformin Fixed-Dose Combination in Healthy Subjects under Fasting Conditions. JournalofBiosciencesandMedicines, 12, 235-250. https://doi.org/10.4236/jbm.2024.129022
